FMP
TransCode Therapeutics, Inc.
RNAZ
NASDAQ
TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. Its cancer agnostic programs comprise TTX-RIGA, an RNAbased agonist of the RIG-I-driven immune response in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines meant to activate cytotoxic immune responses against tumor cells. The company was incorporated in 2016 and is based in Boston, Massachusetts.
0.393 USD
-0.0061 (-1.55%)
About
ceo
Mr. Thomas A. Fitzgerald M.B.A.
sector
Healthcare
industry
Biotechnology
exchange
NASDAQ
Description
TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. Its cancer agnostic programs comprise TTX-RIGA, an RNAbased agonist of the RIG-I-driven immune response in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines meant to activate cytotoxic immune responses against tumor cells. The company was incorporated in 2016 and is based in Boston, Massachusetts.
CIK
0001829635
ISIN
US89357L3033
CUSIP
89357L105
Address
6 Liberty Square
Phone
857-837-3099
Country
US
Employee
8
IPO Date
Jul 8, 2021
Key Executives
Name
Title
Pay
Year Born
Ms. Susan Duggan M.B.A., R.N.
Senior Vice President of Operations
0
N/A
Dr. Zdravka Medarova Ph.D.
Co-Founder & Chief Scientific Officer
0
1975
Dr. Anna Moore Ph.D.
Co-Founder, Scientific Advisor & Member ...
0
1962
Dr. Daniel R. Vlock M.D.
Chief Medical Officer
0
1952
Dr. Philippe P. Calais Ph.D., Pharm., Pharm.D.
Executive Chairman of the Board
100k
1959
Mr. Thomas A. Fitzgerald M.B.A.
Interim Chief Executive Officer, Chief F...
358.14k
1952
As of December 31, 2024, the total employee count stands at 8, with compensation values reflecting the last fiscal year ending on that date. Pay encompasses salary, bonuses, etc., All figures are in USD.
